Research Progress of DcR3 in the Diagnosis and Treatment of Sepsis
International Journal of Molecular Sciences · 18.08.2023 · 24 (16) · 12916
DOI: 10.3390/ijms241612916 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 18.08.2023. Verfasst von Jingqian Su und 4 weiteren Autor:innen. Beteiligte Einrichtung: Fujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, College of Life Science, Fujian Normal University, Fuzhou …. Hauptthemen laut MEDLINE: Sepsis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Fujian Province, China, Fujian Provincial Regional Development Project.
Themen: Sepsis
Abstract (Originalsprache)
Decoy receptor 3 (DcR3), a soluble glycosylated protein in the tumor necrosis factor receptor superfamily, plays a role in tumor and inflammatory diseases. Sepsis is a life-threatening organ dysfunction caused by the dysregulation of the response to infection. Currently, no specific drug that can alleviate or even cure sepsis in a comprehensive and multi-level manner has been found. DcR3 is closely related to sepsis and considerably upregulated in the serum of those patients, and its upregulation is positively correlated with the severity of sepsis and can be a potential biomarker for diagnosis. DcR3 alone or in combination with other markers has shown promising results in the early diagnosis of sepsis. Furthermore, DcR3 is a multipotent immunomodulator that can bind FasL, LIGHT, and TL1A through decoy action, and block downstream apoptosis and inflammatory signaling. It also regulates T-cell and macrophage differentiation and modulates immune status through non-decoy action; therefore, DcR3 could be a potential drug for the treatment of sepsis. The application of DcR3 in the treatment of a mouse model of sepsis also achieved good efficacy. Here, we introduce and discuss the progress in, and suggest novel ideas for, research regarding DcR3 in the diagnosis and treatment of sepsis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, College of Life Science, Fujian Normal University, Fuzhou 350117, China.
ORCID-Profile: Jingqian Su, Qi Chen
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Fujian Province, China
- Fujian Provincial Regional Development Project
Zitieren
APA
Su, J., Tong, Z., Wu, S., Zhou, F., & Chen, Q. (2023). Research Progress of DcR3 in the Diagnosis and Treatment of Sepsis. International Journal of Molecular Sciences, 24(16), 12916. https://doi.org/10.3390/ijms241612916
Vancouver
Su J, Tong Z, Wu S, Zhou F, Chen Q. Research Progress of DcR3 in the Diagnosis and Treatment of Sepsis. International Journal of Molecular Sciences. 2023;24(16):12916. doi:10.3390/ijms241612916
BibTeX
@article{Su2023,
author = {Su, Jingqian and Tong, Zhiyong and Wu, Shun and Zhou, Fen and Chen, Qi},
title = {Research Progress of DcR3 in the Diagnosis and Treatment of Sepsis},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {16},
pages = {12916},
doi = {10.3390/ijms241612916}
}
EUVIMED